secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001493152-23-044387
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mangoceuticals enters licensing deal for Kyzatrex® testosterone capsules with Marius Pharmaceuticals
--------------------------------------------------------------------------------

- Issued 100,000 restricted shares to Marius for non-exclusive license to market Kyzatrex® on MangoRx telehealth platform.
- Two-year initial term; renews automatically if MangoRx maintains at least 2,500 monthly Kyzatrex patients.
- Marius can terminate without cause on 60 days' notice, or if 30% of patient milestone not met within 6 months of launch by Jan 31, 2024.
- MangoRx agrees not to market competing testosterone undecanoate products during term and 12 months after.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315223044387/0001493152-23-044387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315223044387/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-044387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer